Dechra Pharmaceuticals PLC Trading Update and Notice of Half Year Results (2800Y)
13 Gennaio 2022 - 8:00AM
UK Regulatory
TIDMDPH
RNS Number : 2800Y
Dechra Pharmaceuticals PLC
13 January 2022
Thursday, 13 January 2022
Dechra(R) Pharmaceuticals PLC
(Dechra, Group, Company)
Trading Update
The Board of Dechra issues the following unaudited Trading
Update covering the half year reporting period from 1 July to 31
December 2021 (the Period).
The Group is pleased to report that the strong trading
performance in quarter one continued throughout the first half
delivering excellent growth in the Period.
Highlights include:
* Group net revenue for the Period increased by c.15%
at constant exchange rates (CER) (c.10% at actual
exchange rates (AER)).
* European Pharmaceuticals net revenue growth was c.10%
at CER in the Period (AER c.5%), including the
acquisitions of Osurnia(R) (acquired 28 July 2020)
and Tri-Solfen(R) in Australia and New Zealand
(acquired 5 February 2021). Existing net revenues
increased by c.8% at CER in the Period (AER c.3%).
* North American Pharmaceuticals net revenue growth was
c.26% at CER in the Period (AER c.21%).
* Four additional Equine products and two additional
anaesthetic products acquired during the Period for a
combined consideration of U$29 million.
Post Period end:
* Asset purchase agreement signed for the acquisition
of the worldwide rights to verdinexor, branded
Laverdia(R), a novel treatment of all forms and
stages of canine lymphoma in dogs, providing access
to a new niche therapy area.
The outlook for the full financial year is positive and in line
with the upper end of management expectations despite the
continuing COVID-19 disruption. The Group results should continue
to benefit from good growth in the Companion Animal market.
Ian Page, Chief Executive Officer, commented:
"Group performance in the first half has been excellent. Global
trading continues to be strong and our supply chain has been robust
despite COVID-19 related challenges. As expected, Group revenue
growth slowed slightly from the extraordinary levels experienced in
the prior year as markets return to more normal levels, albeit from
a higher base.
We are delighted to have executed a number of product
acquisitions which complement and strengthen our existing portfolio
and also, through Laverdia, take us into a new specialist
therapeutic area. We continue to believe in the ability of our
people to execute our strategy and remain confident in our future
prospects."
Notice of Results
Dechra will announce its Interim Results for the Period on
Monday, 21 February 2022.
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer Office: +44 (0) 1606 814 730
Paul Sandland, Chief Financial Office: +44 (0) 1606 814 730
Officer
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications
Ltd
Fiona Tooley, Director Mobile: +44 (0) 7785 703 523
e-mail: fiona@tooleystreet.com Office: +44 (0) 121 309 0099
Notes:
1) Foreign Exchange Rates:
FY2022 H1 Average: EUR 1.1744: GBP 1.0; USD 1.3635: GBP 1.0
FY2022 H1 Closing: EUR 1.1901: GBP 1.0; USD 1.3479: GBP 1.0
FY2021 H1 Average: EUR 1.1060: GBP 1.0; USD 1.3060: GBP 1.0
FY2021 H1 Closing: EUR 1.1123: GBP 1.0; USD 1.3649: GBP 1.0
FY2021 Average: EUR 1.1287: GBP 1.0; USD 1.3466: GBP 1.0
FY2021 Closing: EUR 1.1654: GBP 1.0; USD 1.3850: GBP 1.0
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture marketing and sales of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
For more information, please visit: www.dechra.com .
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC. Tri-Solfen is a trademark of Animal
Ethics Pty Ltd.
Forward Looking Statement
This document may contain certain forward-looking statements.
The forward-looking statements reflect the knowledge and
information available to the Company during the preparation and up
to the publication of this document. By their very nature, these
statements depend upon circumstances and relate to events that may
occur in the future thereby involve a degree of uncertainty.
Therefore, nothing in this document should be construed as a profit
forecast by the Company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTDGGDBBGBDGDD
(END) Dow Jones Newswires
January 13, 2022 02:00 ET (07:00 GMT)
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Apr 2023 a Apr 2024